Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -19.63% | -6.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.71% | 16.00% | |||
| Operating Income | 16.71% | -16.00% | |||
| Income Before Tax | 27.13% | -29.23% | |||
| Income Tax Expenses | -110.71% | 100.00% | |||
| Earnings from Continuing Operations | 27.19% | -29.26% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 17.65% | 44.68% | |||
| Net Income | 27.22% | -29.25% | |||
| EBIT | 16.71% | -16.00% | |||
| EBITDA | 16.88% | -15.95% | |||
| EPS Basic | 27.34% | -26.24% | |||
| Normalized Basic EPS | 29.16% | -28.40% | |||
| EPS Diluted | 27.34% | -26.24% | |||
| Normalized Diluted EPS | 29.16% | -28.40% | |||
| Average Basic Shares Outstanding | 2.75% | 0.67% | |||
| Average Diluted Shares Outstanding | 2.75% | 0.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||